ストックスクリーナーアプリを入手
0.868
3.27%
-0.0293
アフターアワーズ：
.87
0.002
+0.23%
前日終値:
$0.8973
開ける：
$0.8846
24時間の取引高:
1.26M
Relative Volume:
0.37
時価総額：
$339.79M
収益：
$86.26M
当期純損益:
$-50.08M
株価収益率:
-3.5443
EPS:
-0.2449
ネットキャッシュフロー:
$-94.48M
1週間 パフォーマンス:
+4.18%
1か月 パフォーマンス:
+5.51%
6か月 パフォーマンス:
-38.00%
1年 パフォーマンス:
-34.74%
1日の値動き範囲:
$0.855
$0.9004
1週間の範囲:
$0.766
$0.9165
52週間の値動き範囲:
$0.7029
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Compare LAB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.868 | 303.23M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-27 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | 開始されました | TD Cowen | Buy |
| 2024-04-04 | 開始されました | Jefferies | Buy |
| 2023-07-12 | 開始されました | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc (LAB) 最新ニュース
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences - Moomoo
- SEC.gov
Standard BioTools (LAB) plans sale of Mass Cytometry business alongside Treeline deal - Stock Titan
Standard BioTools sells mass cytometry unit, gets $30M buyout - Investing.com
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock Titan
Standard BiotoolsEnters Termination, Waiver And Release Agreement With Illumina On July 24, 2026SEC Filing - TradingView
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina - TradingView
Standard BioTools Announces Sale of Mass Cytometry Business - GlobeNewswire
Standard BioTools Inc (LAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Form 4 Standard Biotools Inc For: 27 July By Investing.com - Investing.com Canada
Standard BioTools Inc. (LAB) CFO share withholding for tax obligations - Stock Titan
Standard BioTools Inc. Revenue Breakdown – GETTEX:FLB - TradingView
Standard BioTools Inc (LAB) Income Statement - TradingKey
LAB|Standard BioTools Inc|Price:0.833|Chg%:-0.042 - TradingKey
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Standard BioTools Inc (LAB) Institutional Confidence - TradingKey
Standard BioTools Inc (LAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Standard BioTools Inc (LAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
LAB|Standard BioTools Inc|Price:0.802|Chg%:-0.031 - TradingKey
Standard BioTools Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Standard BioTools (NASDAQ: LAB) warned on Nasdaq minimum bid-price compliance - Stock Titan
Standard BioTools gets Nasdaq notice for failing $1 minimum bid price rule - Bitget
Standard BioTools Inc (LAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 - Investing News Network
Standard BioTools will post its next update after market close Aug. 5 - Stock Titan
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? - TradingView
Standard BioTools files merger registration with Treeline By Investing.com - Investing.com South Africa
Standard BioTools (LAB) details Treeline merger, $900M cash and TLN-121 data - Stock Titan
Standard BioTools files merger registration with Treeline - Investing.com
Standard BioTools Files S-4 for Merger with Treeline Biosciences, Highlighting Promising TLN-121 Clinical Data and Strong Cash Position - Quiver Quantitative
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction - GlobeNewswire
Standard BioTools (NASDAQ: LAB) outlines all-stock Treeline Biosciences merger and CVR plan - Stock Titan
Standard Biotools Inc (FLB) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
Standard BioTools (LAB) reports Q1 loss, tops revenue estimates - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB - Sahm
Standard BioTools (LAB) Rallies 4.4% After Support Test – Key Resistance in SightETF Creation Redemption - dars.gov.et
FLDM4094699 Bond Profile — Key Metrics - TradingView
FLDM4094699 Bond Redemption Profile - TradingView
Standard Biotools Inc (FLB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Standard Biotools Inc (FLB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Standard BioTools (LAB) Holds Above Key Support After Modest UptickBuffered ETF - dars.gov.et
Standard BioTools (LAB) Slides to $0.92 – Support Test in FocusInverse ETF Flow - dars.gov.et
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Standard BioTools (LAB) Surges Over 5%, Nears Key Resistance at $0.96RTH Profile - dars.gov.et
Standard BioTools Inc. (LAB) Surges 5% as Stock Approaches Key Resistance LevelOvernight Profile - dars.gov.et
Standard BioTools (LAB) Surges 5.36% as Shares Test Key Resistance LevelWave Truncation - dars.gov.et
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Turns Loss Estimate into ProfitEarnings Outlook Update - DonanımHaber
Standard Biotools Inc (LAB) 財務データ
収益
当期純利益
現金流量
EPS
Standard Biotools Inc (LAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kim Hanjoon Alex | Chief Financial Officer |
Apr 06 '26 |
Option Exercise |
0.00 |
70,183 |
0 |
2,800,702 |
| Casdin Partners Master Fund, L | Director |
Dec 04 '25 |
Buy |
1.45 |
150,000 |
217,020 |
72,100,000 |
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
1.04%
11.95%
大文字化:
|
ボリューム (24 時間):